Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • GOT1 Inhibition Reprograms Glutamine Metabolism in Pancreati

    2026-06-11

    Targeting GOT1: Metabolic Reprogramming in Pancreatic Cancer

    Study Background and Research Question

    Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, with a five-year survival rate below 10% due to late diagnosis and limited therapeutic options. A hallmark of PDAC is its distinctive metabolic reprogramming, particularly the reliance on glutamine metabolism to fuel anabolic growth, support redox balance, and maintain cellular proliferation. Central to this process is the enzyme glutamate-oxaloacetate transaminase 1 (GOT1), which catalyzes the cytosolic conversion of aspartate to oxaloacetate, thereby sustaining NADPH production and reactive oxygen species (ROS) detoxification. The reference study (Yang et al., 2022) investigates whether pharmacologic inhibition of GOT1 can disrupt these metabolic networks and suppress PDAC cell viability.

    Key Innovation from the Reference Study

    The study introduces ziprasidone, an FDA-approved antipsychotic, as a novel inhibitor of GOT1 with non-competitive enzymatic inhibition. Unlike previously described GOT1 inhibitors, ziprasidone not only binds with high affinity but also demonstrates robust selectivity in both in vitro and in vivo models. This repurposing of a clinically available compound marks a significant advance, as it provides a practical route for rapid translational exploration and mechanistic dissection of GOT1's role in cancer metabolism.

    Methods and Experimental Design Insights

    The research team employed a multi-tiered approach combining biochemical assays, cell-based phenotyping, metabolomics, and xenograft models. Key methodological highlights include:

    • Enzyme kinetics and binding assays (microscale thermophoresis, CETSA) to confirm ziprasidone’s non-competitive inhibition of GOT1.
    • Cell proliferation, migration, and apoptosis assays in PDAC cell lines treated with ziprasidone, with and without GOT1 knockdown via RNA interference.
    • Metabolomic profiling to track glutamine flux and redox state, including NADPH/NADP+ ratios and ROS levels.
    • In vivo efficacy studies using SW1990 cell-derived xenografts in mice, measuring tumor growth and histological markers.

    Critically, the study included controls for glutamine withdrawal and genetic ablation of GOT1 to delineate the specificity of ziprasidone’s action on metabolic reprogramming.

    Core Findings and Why They Matter

    The reference study (Yang et al., 2022) presents several pivotal findings:

    • GOT1 is Essential for PDAC Redox Maintenance: GOT1 upregulation facilitates glutamine-derived aspartate conversion, sustaining NADPH pools and limiting ROS accumulation.
    • Ziprasidone Selectively Inhibits GOT1: The drug binds GOT1 in a non-competitive manner, disrupting its catalytic activity and downstream glutamine metabolism.
    • Redox Imbalance and Growth Suppression: Inhibition of GOT1 by ziprasidone increases intracellular ROS, reduces NADPH, and triggers apoptosis in PDAC cells. This is accompanied by marked reductions in cell proliferation and migration.
    • Dependency on GOT1: Knockdown of GOT1 blunts the anti-proliferative effects of ziprasidone, confirming on-target action.
    • In Vivo Efficacy: Treatment with ziprasidone significantly suppresses tumor growth in mouse xenograft models, with no overt toxicity to normal tissues.

    These findings expand the understanding of metabolic vulnerabilities in PDAC, suggesting that therapeutic targeting of glutamine metabolism, particularly through GOT1 inhibition, can destabilize redox homeostasis and selectively impair tumor progression.

    Comparison with Existing Internal Articles

    The mechanistic insights from this study align with established roles for reduced glutathione (GSH) in redox regulation. As discussed in "L-Glutathione Reduced: Core Mechanisms, Research, and Limits", GSH serves as a primary endogenous antioxidant tripeptide that directly scavenges ROS and supports cellular detoxification. The disruption of NADPH generation by GOT1 inhibition, as shown in the reference paper, would be expected to compromise the ability of cells to regenerate reduced glutathione, thereby amplifying oxidative stress—a relationship also highlighted in "L-Glutathione Reduced: Redox Control for Oxidative Stress Research". These articles reinforce the significance of redox biomarkers and the utility of reduced glutathione in modeling oxidative stress responses in cancer research workflows. Moreover, the use of reduced glutathione as a glutathione S-transferase substrate and in cardiovascular disease research, as referenced in internal reviews, underlines its value as a tool for dissecting metabolic pathways parallel to those targeted by GOT1 inhibition.

    Limitations and Transferability

    While the study provides compelling evidence for GOT1 as a metabolic vulnerability in PDAC, several limitations should be noted:

    • Model Specificity: The primary in vivo data derive from a single PDAC cell line xenograft. Broader validation in genetically diverse models is warranted.
    • Tumor Selectivity: Although ziprasidone showed minimal toxicity in normal tissues, the long-term safety and pharmacodynamics in non-cancerous contexts remain to be established.
    • Redox Complexity: The interplay between NADPH, ROS, and glutathione pools is intricate; direct measurements of reduced glutathione levels in the context of GOT1 inhibition would further clarify mechanistic links.
    • Clinical Translation: Repurposing ziprasidone for oncology is promising, but dosing, off-target effects, and patient stratification need rigorous clinical assessment.

    Transferability is high for mechanistic studies of redox balance and glutamine metabolism in cancer, but caution is needed in extending conclusions to non-oncologic diseases or unrelated metabolic contexts.

    Protocol Parameters

    • Ziprasidone treatment: In vitro, PDAC cells were treated with ziprasidone at concentrations ranging from 10–40 μM for 24–72 hours to assess proliferation, apoptosis, and redox state.
    • GOT1 knockdown: RNA interference was used to reduce GOT1 expression prior to pharmacological inhibition, clarifying the specificity of metabolic effects.
    • Redox assays: NADPH/NADP+ and ROS levels were measured using established fluorometric and colorimetric kits; reduced glutathione can be quantified via enzymatic cycling assays in parallel workflows (see internal protocols).
    • In vivo xenograft studies: SW1990 cells injected subcutaneously in nude mice, with ziprasidone administered intraperitoneally at 10 mg/kg, three times per week for 21 days.
    • Glutathione S-transferase substrate assays: Reduced glutathione is used at ≥1 mM as a substrate for GST enzymatic activity in affinity chromatography and oxidative stress modeling (reviewed protocols).

    Research Support Resources

    Researchers investigating metabolic reprogramming and redox homeostasis in cancer can leverage reduced glutathione as both a substrate and biomarker. For high-fidelity oxidative stress assays, L-Glutathione Reduced (SKU B7775) from APExBIO offers controlled purity and solubility for sensitive biochemical workflows. Its validated application as a glutathione S-transferase substrate and antioxidant in cancer research supports the mechanistic exploration of pathways highlighted in the GOT1 inhibition study. For further reading and best practices, internal articles such as "L-Glutathione Reduced: Optimizing Redox Assays in Cancer Research" provide detailed protocol recommendations and troubleshooting tips.